Abelson Tyrosine Kinase Inhibitors in Parkinson's Disease and Lewy Body Dementia: A Systematic Review, Meta-analysis, and Meta-regression.
Giovanni Gosch BertonAmanda Cyntia Lima Fonseca RodriguesRafael Dos Santos BorgesNicole Rodrigues CardosoThiago Abrahão de OliveiraMarcos Vinícius Oliveira MarquesPublished in: Clinical neuropharmacology (2024)
Nilotinib (300 mg) proved effective postsensitivity analysis, unlike lower doses and bosutinib in Parkinson's disease/Lewy body dementia. Abl TKIs showed reduced efficacy in younger, more impaired patients, indicating the need for further testing with higher-potency drugs in patients who have diseases that are in the early stage but with a later onset.